The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers.

Eur J Nucl Med Mol Imaging · 2021 · PMC8175325 · PMID 33677733

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Mielke and colleagues [ 77 ] then described an electrochemiluminescence (ECL) method, developed by Eli Lilly, to measure p-tau181 which also reported highly significant increases in AD but importantly demonstrated a strong relationship with amyloid and tau PET.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.